EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

The Therapeutic Efficacy of Drugs Targeting the NO‐sGC‐cGMP Pathway in Treatment of Patients With Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review

Abdullah A Alqarni iD, Rawan H Aljedani, Abdulelah M Aldhahir iD, Ahmed H Alasimi iD, Abdulkareem A AlGarni, Jaber S Alqahtani iD, Saeed Mardy Alghamdi iD, Rayan A Siraj iD, Aminah Mengash iD, Hassan Alwafi

Pulmonary Circulation · 2026-07 · 16 (3)

DOI: 10.1002/pul2.70337 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pulmonary Circulation, online erschienen am 15.07.2026. Verfasst von Abdullah A Alqarni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences King Abdulaziz University Jeddah Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct and potentially curable form of pulmonary hypertension; however, a substantial proportion of patients remain inoperable or experience persistent or recurrent disease. Pharmacological therapies targeting the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO–sGC–cGMP) pathway have emerged as promising treatment options. Therefore, this systematic review aimed to comprehensively evaluate the therapeutic efficacy of drugs targeting the NO–sGC–cGMP pathway on clinical outcomes in patients with CTEPH. We conducted a comprehensive search of electronic databases, including Embase, MEDLINE, Cochrane Library, and Scopus databases from inception to December 1, 2025. Studies involving adult patients with confirmed CTEPH receiving NO–sGC–cGMP pathway‐targeted therapies were included. Exclusion criteria encompassed case reports, systematic reviews, review articles, conference abstracts with no full text (since they were not peer‐reviewed), non‐full‐text articles, non‐English manuscripts, opinion articles, and book chapters. Risk of bias was assessed using the Cochrane RoB 2 tool and the Newcastle–Ottawa Scale. A total of 23 studies involving 2815 patients were included. The most frequently investigated agents were riociguat and sildenafil. Fourteen of 15 studies demonstrated significant improvements in exercise capacity, with consistent findings reported in major trials such as CHEST‐1 and its long‐term extension, CHEST‐2. All 16 studies assessing pulmonary hemodynamics reported significant improvements in mPAP, PVR, and CO. Additionally, 12 studies showed reductions in NT‐proBNP levels and improvements in WHO‐FC, indicating enhanced functional status. Quality of life was assessed in two studies, both of which demonstrated favorable outcomes. Furthermore, three studies reported improvements in right ventricular function and risk stratification. Pharmacological agents targeting the NO–sGC–cGMP pathway, particularly riociguat and sildenafil, demonstrate consistent improvements in exercise capacity, pulmonary hemodynamics, functional status, and biomarkers in patients with CTEPH. These findings support their role as effective therapeutic options, especially in inoperable or persistent CTEPH. Nevertheless, further large‐scale, high‐quality randomized controlled trials are warranted to strengthen the evidence base and optimize treatment strategies. Systematic review registration: CRD42024510274, https://www.crd.york.ac.uk/PROSPERO/view/CRD42024510274 .

Schlagwörter

Stichwörter der Autor:innen

COPDPDE5 inhibitorsgroup 3 PHnitric oxide pathwayphosphodiesterase‐5 (PDE5) inhibitorspulmonary hypertensionsGC stimulatorssildenafilsoluble guanylate cyclase stimulatorstadalafil

Autor:innen und Institutionen

  • Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences King Abdulaziz University Jeddah Saudi Arabia.
  • Respiratory Therapy Unit King Abdulaziz University Hospital Jeddah Saudi Arabia.
  • Department of Respiratory Therapy Armed Forces Hospitals Taif Region Taif Saudi Arabia.
  • Respiratory Therapy Program, Department of Nursing, College of Nursing and Health Sciences Jazan University Jazan Saudi Arabia.
  • National Heart and Lung Institute Imperial College London London UK.
  • College of Applied Medical Sciences King Saud bin Abdulaziz University for Health Sciences Al Ahsa Saudi Arabia.

ORCID-Profile: Abdullah A Alqarni, Abdulelah M Aldhahir, Ahmed H Alasimi, Jaber S Alqahtani, Saeed Mardy Alghamdi, Rayan A Siraj, Aminah Mengash

Förderung

  • King Abdulaziz University

Zitieren

APA

Alqarni, A. A., Aljedani, R. H., Aldhahir, A. M., Alasimi, A. H., AlGarni, A. A., Alqahtani, J. S., Alghamdi, S. M., Siraj, R. A., Mengash, A., & Alwafi, H. (2026). The Therapeutic Efficacy of Drugs Targeting the NO‐sGC‐cGMP Pathway in Treatment of Patients With Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review. Pulmonary Circulation, 16(3). https://doi.org/10.1002/pul2.70337

Vancouver

Alqarni AA, Aljedani RH, Aldhahir AM, Alasimi AH, AlGarni AA, Alqahtani JS, et al. The Therapeutic Efficacy of Drugs Targeting the NO‐sGC‐cGMP Pathway in Treatment of Patients With Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review. Pulmonary Circulation. 2026;16(3). doi:10.1002/pul2.70337

BibTeX
@article{Alqarni2026,
  author = {Alqarni, Abdullah A and Aljedani, Rawan H and Aldhahir, Abdulelah M and Alasimi, Ahmed H and AlGarni, Abdulkareem A and Alqahtani, Jaber S and Alghamdi, Saeed Mardy and Siraj, Rayan A and Mengash, Aminah and Alwafi, Hassan},
  title = {The Therapeutic Efficacy of Drugs Targeting the NO‐sGC‐cGMP Pathway in Treatment of Patients With Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review},
  journal = {Pulmonary Circulation},
  year = {2026},
  volume = {16},
  number = {3},
  doi = {10.1002/pul2.70337}
}
Kostenlos starten →